Novartis Plans Fast Entresto Launch Following FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
The company’s first-in-class angiotensin receptor neprilysin inhibitor was approved by FDA for heart failure with reduced ejection fraction July 7, earlier than expected.